Product Sheet

GLP-1R Antagonist Antibodies for Rare Metabolic Diseases, Primed for Development

Severe and persistent hypoglycemia (low blood glucose) due to excess insulin secretion from pancreatic β-cells can result in serious clinical outcomes including seizures, brain damage, and death. There are limited therapeutic options for this metabolic dysfunction, which can be caused by certain medical conditions:

 • Post-bariatric hypoglycemia (PBH)

 • Congenital hyperinsulinism (CHI)

 • Insulinoma